Show simple item record

dc.contributor.authorHaslett, Kate
dc.contributor.authorBayman, Neil A
dc.contributor.authorFranks, K.
dc.contributor.authorGroom, N.
dc.contributor.authorHarden, S. V.
dc.contributor.authorHarris, C.
dc.contributor.authorHanna, G.
dc.contributor.authorHarrow, S.
dc.contributor.authorHatton, M.
dc.contributor.authorMcCloskey, P.
dc.contributor.authorMcDonald, F.
dc.contributor.authorRyder, W. D.
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2021-01-06T11:15:24Z
dc.date.available2021-01-06T11:15:24Z
dc.date.issued2020en
dc.identifier.citationHaslett K, Bayman N, Franks K, Groom N, Harden SV, Harris C, et al. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. Int J Radiat Oncol Biol Phys. 2020.en
dc.identifier.pmid33232772en
dc.identifier.doi10.1016/j.ijrobp.2020.11.040en
dc.identifier.urihttp://hdl.handle.net/10541/623637
dc.description.abstractPurpose: Not all patients with stage III NSCLC are suitable for concurrent chemoradiotherapy (cCRT). Local failure rate is high for sequential CRT and as such, there is a rationale for treatment intensification. Methods and materials: Isotoxic intensity modulated radiotherapy (IMRT) is a multicentre feasibility study that combines different intensification strategies including hyperfractionation, acceleration and dose escalation facilitated by IMRT. Patients with unresectable stage III NSCLC, ECOG PS 0-2 and unsuitable for cCRT were recruited. A minimum of 2 cycles of platinum-based chemotherapy was compulsory before starting radiotherapy (RT). Radiation dose was increased until a maximum dose of 79.2Gy was reached or ≥ 1 of the organs at risk met pre-defined constraints. RT was delivered in 1.8Gy fractions twice-daily and an RT quality assurance programme was implemented. The primary objective was the delivery of isotoxic IMRT to a dose of > 60Gy equivalent dose in 2Gy fractions (EQD2 assuming an α/β ratio of 10 Gy for acute reacting tissues). Results: 37 patients were recruited from 7 UK centres. Median age = 69.9 years (range 46-86). Male:Female ratio = 17:18. ECOG PS=0, 5 (14.2%), PS=1, 27 (77.1%), PS=2, 3 (8.6%). Stage IIIA:IIIB ratio 22 (62.9%):13 (37.1%). Of 37 patients, 2 (5.4%) failed to achieve EQD2 >60Gy. Median prescribed tumor dose was 77.4Gy (61.2 - 79.2Gy). Maximum dose of 79.2Gy was achieved in 14 (37.8%) patients. Grade 3 esophagitis was reported in 2 patients and no patients developed grade 3-4 pneumonitis. There were 3 grade 5 events: acute radiation pneumonitis, bronchopulmonary haemorrhage and acute lung infection. Median follow-up at time of analysis was 25.4 (8.0 - 44.2) months for 11 out of 35 survivors. The median survival was 18.1 months with 95% CI (13.9, 30.6), 2-year overall survival was 33.6%; 95% CI (17.9, 50.1) and progression-free survival was 23.9%; 95% CI (11.3, 39.1). Conclusions: Isotoxic IMRT is a well-tolerated and feasible approach to treatment intensification.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ijrobp.2020.11.040en
dc.titleIsotoxic intensity modulated radiotherapy in stage III NSCLC - a feasibility studyen
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Wilmslow Road, Manchester, UKen
dc.identifier.journalInternational Journal of Radiation Oncology Biology Physicsen
dc.description.noteen]
refterms.dateFOA2021-01-06T13:11:54Z


Files in this item

Thumbnail
Name:
33232772.pdf
Size:
333.6Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record